First-line immune checkpoint inhibitors combined with chemotherapy in advanced large-cell neuroendocrine carcinoma of the lung: a real-world retrospective study.

ABSTRACT:

Background

Large-cell neuroendocrine carcinoma of the lung (LCNEC) shares clinicopathological features with both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Owing to its neuroendocrine characteristics, the treatment of LCNEC often follows paradigms established for SCLC. Immune checkpoint inhibitors (ICIs) have become the standard first-line therapy for extensive-stage SCLC (ES-SCLC), but evidence supporting the use of ICIs in advanced LCNEC remains limited. This study aimed to evaluate the efficacy and prognosis of first-line ICIs in patients with advanced LCNEC.

Methods

We retrospectively analyzed 31 patients with stage IV LCNEC treated at Inner Mongolia People's Hospital from January 2019 to December 2024. Of these, 14 patients received ICIs plus

SUBMITTER: Ji B 

PROVIDER: S-EPMC12668943 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature